FeesSafety
Pluang+

Patria reports Q3 2026 earnings with $7.2M net income and $52.8M fee-related earnings, beating fundraising targets early.

Company Fundamentals
03 Nov 2026, 13:00 WIB
GlobeNewsWire
View Source
Bullish
Patria reports Q3 2026 earnings with $7.2M net income and $52.8M fee-related earnings, beating fundraising targets early.

Patria Investments Limited announced its unaudited Q3 2026 results, reporting $7.2 million net income and $52.8 million in fee-related earnings, a 7% increase from the previous year. The company raised $2.4 billion in the quarter and $6.9 billion year-to-date, surpassing its full-year fundraising goal ahead of schedule. With over 85% of its fee-earning assets under management performing at or above benchmarks, Patria is confident in meeting its 2026 guidance and 2027 targets. The firm declared a quarterly dividend of $0.1625 per share, payable in December, and will host a conference call to discuss results.

Patria Investments Limited's Q3 2026 earnings report provides context for financial sector activity. For readers following Financials, here is Pluang's market snapshot as of Nov 03, 2026 16:11 WIB: out of 142 priced US Financials stocks, 63 rose and 67 fell. Notable movers include Raymond James Financial at USD 157.25 with a -3.11% change, Brookfield Asset Management at USD 49.96 with a -2.93% change, and Ally Financial at USD 39.62 with a +2.63% change.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App